Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2018 Jan;43(1):25-28.

Edaravone (Radicava): A Novel Neuroprotective Agent for the Treatment of Amyotrophic Lateral Sclerosis

Martin Paspe Cruz

Edaravone (Radicava): A Novel Neuroprotective Agent for the Treatment of Amyotrophic Lateral Sclerosis

Martin Paspe Cruz. P T. 2018 Jan.

Abstract

Edaravone (Radicava): a novel neuroprotective agent for the treatment of amyotrophic lateral sclerosis.

PubMed Disclaimer

Conflict of interest statement

Disclosure: The author reports no commercial or financial interests in regard to this article.

Figures

Figure 1
Figure 1
Chemical Structure of Edaravone
See this image and copyright information in PMC

References

    1. Association ALS. Quick facts about ALS and the ALS Association. [Accessed September 15, 2017]. Available at: www.alsa.org/news/media/quick-facts.html.
    1. Hardiman O, van den Berg LH, Kiernan MC. Clinical diagnosis and management of amyotrophic lateral sclerosis. Nat Rev Neurol. 2011;7(11):639–649. - PubMed
    1. Walling AD. Amyotrophic lateral sclerosis: Lou Gehrig’s disease. Am Fam Physician. 1999;59(6):1489–1496. - PubMed
    1. Kimura F, Fujimura C, Ishida S, et al. Progression rate of ALSFRS-R at time of diagnosis predicts survival time in ALS. Neurology. 2006;66(2):265–267. - PubMed
    1. King SJ, Duke MM, O’Connor BA. Living with amyotrophic lateral sclerosis/motor neurone disease (ALS/MND): decision-making about “ongoing change and adaptation”. J Clin Nurs. 2009;18(5):745–754. - PubMed

LinkOut - more resources